• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于监测疫苗效力的新型肠道病毒71型单克隆抗体的研发。

Development of a novel EV-A71 monoclonal antibody for monitoring vaccine potency.

作者信息

Le Thi-Hong-Loc, Weng Tzu-Yu, Yen Hua, Chia Min-Yuan, Lee Min-Shi

机构信息

National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Miaoli, Taiwan.

Institute of Bioinformatics and Structural Biology, College of Life Sciences and Medicine, National Tsing Hua University, Hsinchu, Taiwan.

出版信息

PLoS Negl Trop Dis. 2025 Jun 3;19(6):e0013127. doi: 10.1371/journal.pntd.0013127. eCollection 2025 Jun.

DOI:10.1371/journal.pntd.0013127
PMID:40460346
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12157779/
Abstract

Enterovirus A71 (EV-A71) is one of the major causes of hand, foot, and mouth disease (HFMD), primarily affecting children under five. It can lead to neurological and cardiac complications, or even death, in some cases. Inactivated monovalent vaccines have been licensed in China and Taiwan; however, the stability of EV-A71 vaccines is often compromised by factors such as extreme temperatures or ultraviolet (UV) irradiation. Currently, no commercially available tools can assess the stability of EV-A71 throughout vaccine development. In this study, we report the development of a monoclonal antibody (mAb), NHRI2016-1, which can be used in in vitro immunoassays to evaluate EV-A71 vaccine potency and effectiveness. NHRI2016-1 exclusively recognizes effective EV-A71 antigens in in vitro potency assays. Similarly, rat experiment confirmed that effective vaccine antigens could induce neutralizing antibodies, while ineffective antigens could not. Thus, NHRI2016-1 shows potential for correlating in vitro potency with in vivo immunogenicity of EV-A71 vaccine antigens. These data suggest that NHRI2016-1 could be a promising tool for characterizing EV-A71 vaccines and monitoring vaccine potency.

摘要

肠道病毒A71(EV - A71)是手足口病(HFMD)的主要病因之一,主要影响五岁以下儿童。在某些情况下,它可导致神经和心脏并发症,甚至死亡。灭活单价疫苗已在中国和台湾获得许可;然而,EV - A71疫苗的稳定性常常受到极端温度或紫外线(UV)照射等因素的影响。目前,在整个疫苗研发过程中,没有可用于评估EV - A71稳定性的商业工具。在本研究中,我们报告了一种单克隆抗体(mAb)NHRI2016 - 1的研发情况,该抗体可用于体外免疫测定,以评估EV - A71疫苗的效力和有效性。在体外效力测定中,NHRI2016 - 1仅识别有效的EV - A71抗原。同样,大鼠实验证实,有效的疫苗抗原可诱导中和抗体,而无效抗原则不能。因此,NHRI2016 - 1显示出将EV - A71疫苗抗原的体外效力与体内免疫原性相关联的潜力。这些数据表明,NHRI2016 - 1可能是一种用于鉴定EV - A71疫苗和监测疫苗效力的有前景的工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b486/12157779/7871d26eb928/pntd.0013127.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b486/12157779/489538da5bff/pntd.0013127.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b486/12157779/3bd2fdb363ac/pntd.0013127.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b486/12157779/8c4d8b47beaa/pntd.0013127.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b486/12157779/ee6ac6982a8a/pntd.0013127.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b486/12157779/7baa8177655c/pntd.0013127.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b486/12157779/7871d26eb928/pntd.0013127.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b486/12157779/489538da5bff/pntd.0013127.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b486/12157779/3bd2fdb363ac/pntd.0013127.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b486/12157779/8c4d8b47beaa/pntd.0013127.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b486/12157779/ee6ac6982a8a/pntd.0013127.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b486/12157779/7baa8177655c/pntd.0013127.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b486/12157779/7871d26eb928/pntd.0013127.g006.jpg

相似文献

1
Development of a novel EV-A71 monoclonal antibody for monitoring vaccine potency.用于监测疫苗效力的新型肠道病毒71型单克隆抗体的研发。
PLoS Negl Trop Dis. 2025 Jun 3;19(6):e0013127. doi: 10.1371/journal.pntd.0013127. eCollection 2025 Jun.
2
A nucleoside-modified mRNA vaccine prevents enterovirus A71 infection in mouse model.一种核苷修饰的mRNA疫苗可预防小鼠模型中的肠道病毒A71感染。
Front Immunol. 2025 Feb 12;16:1535758. doi: 10.3389/fimmu.2025.1535758. eCollection 2025.
3
Enterovirus A71 Containing Codon-Deoptimized VP1 and High-Fidelity Polymerase as Next-Generation Vaccine Candidate.含密码子去优化 VP1 和高保真聚合酶的肠道病毒 A71 作为下一代疫苗候选物。
J Virol. 2019 Jun 14;93(13). doi: 10.1128/JVI.02308-18. Print 2019 Jul 1.
4
Effectiveness of EV-A71 vaccination in prevention of paediatric hand, foot, and mouth disease associated with EV-A71 virus infection requiring hospitalisation in Henan, China, 2017-18: a test-negative case-control study.2017-18 年中国河南针对肠道病毒 71 型(EV-A71)感染需要住院治疗的手足口病的 EV-A71 疫苗效力:一项病例对照研究
Lancet Child Adolesc Health. 2019 Oct;3(10):697-704. doi: 10.1016/S2352-4642(19)30185-3. Epub 2019 Jul 30.
5
Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles.柯萨奇病毒 A6 和 A10 病毒粒子的免疫学和生化特性。
Antiviral Res. 2016 May;129:58-66. doi: 10.1016/j.antiviral.2016.02.008. Epub 2016 Feb 17.
6
The efficacy and effectiveness of enterovirus A71 vaccines against hand, foot, and mouth disease: A systematic review and meta-analysis.肠道病毒A71型疫苗对手足口病的疗效和有效性:一项系统评价和荟萃分析。
PLoS One. 2025 May 22;20(5):e0323782. doi: 10.1371/journal.pone.0323782. eCollection 2025.
7
Enterovirus A71 vaccine effectiveness in preventing enterovirus A71 infection among medically-attended hand, foot, and mouth disease cases, Beijing, China.肠道病毒 A71 疫苗在中国北京针对有医疗就诊的手足口病病例中预防肠道病毒 A71 感染的效果。
Hum Vaccin Immunother. 2019;15(5):1183-1190. doi: 10.1080/21645515.2019.1581539. Epub 2019 Mar 20.
8
Is a multivalent hand, foot, and mouth disease vaccine feasible?多价手足口病疫苗是否可行?
Hum Vaccin Immunother. 2015;11(11):2688-704. doi: 10.1080/21645515.2015.1049780. Epub 2015 May 26.
9
Effectiveness of the enterovirus A71 vaccine on hand, foot, and mouth disease: a real-world study in China.肠道病毒71型疫苗对手足口病的有效性:一项在中国的真实世界研究。
Clin Microbiol Infect. 2025 Feb;31(2):258-265. doi: 10.1016/j.cmi.2024.09.020. Epub 2024 Sep 27.
10
Safety and Immunogenicity of a Stable, Cold-Adapted, Temperature-Sensitive/Conditional Lethal Enterovirus A71 in Monkey Study.稳定的、冷适应的、温度敏感/条件致死性肠道病毒 A71 在猴研究中的安全性和免疫原性。
Viruses. 2021 Mar 9;13(3):438. doi: 10.3390/v13030438.

本文引用的文献

1
A Critical Review on Ultraviolet Disinfection Systems against COVID-19 Outbreak: Applicability, Validation, and Safety Considerations.关于针对新冠疫情的紫外线消毒系统的批判性综述:适用性、验证及安全考量
ACS Photonics. 2020 Oct 14;7(11):2941-2951. doi: 10.1021/acsphotonics.0c01245. eCollection 2020 Nov 18.
2
Analysis of the epidemiological trends of enterovirus A in Asia and Europe.亚洲和欧洲肠道病毒A的流行病学趋势分析。
J Infect Chemother. 2023 Mar;29(3):316-321. doi: 10.1016/j.jiac.2022.12.006. Epub 2022 Dec 14.
3
Development of functionally relevant potency assays for monovalent and multivalent vaccines delivered by evolving technologies.
通过不断发展的技术递送的单价和多价疫苗的功能相关效力测定方法的开发。
NPJ Vaccines. 2022 May 5;7(1):50. doi: 10.1038/s41541-022-00470-4.
4
Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial.一种灭活佐剂肠道病毒71型疫苗在婴幼儿中的有效性、安全性及免疫原性:一项多区域、双盲、随机、安慰剂对照的3期试验
Lancet. 2022 Apr 30;399(10336):1708-1717. doi: 10.1016/S0140-6736(22)00313-0. Epub 2022 Apr 12.
5
Changing epidemiology of hand, foot, and mouth disease in China, 2013-2019: a population-based study.2013 - 2019年中国手足口病流行病学变化:一项基于人群的研究
Lancet Reg Health West Pac. 2022 Jan 2;20:100370. doi: 10.1016/j.lanwpc.2021.100370. eCollection 2022 Mar.
6
UVC disinfects SARS-CoV-2 by induction of viral genome damage without apparent effects on viral morphology and proteins.UVC 通过诱导病毒基因组损伤来消毒 SARS-CoV-2,而对病毒形态和蛋白质没有明显影响。
Sci Rep. 2021 Jul 5;11(1):13804. doi: 10.1038/s41598-021-93231-7.
7
The life cycle of non-polio enteroviruses and how to target it.非脊髓灰质炎肠道病毒的生命周期及其靶向方法。
Nat Rev Microbiol. 2018 Jun;16(6):368-381. doi: 10.1038/s41579-018-0005-4.
8
Development of a high-growth enterovirus 71 vaccine candidate inducing cross-reactive neutralizing antibody responses.开发一种诱导产生交叉反应性中和抗体应答的高增长肠道病毒 71 疫苗候选物。
Vaccine. 2018 Feb 21;36(9):1167-1173. doi: 10.1016/j.vaccine.2018.01.041.
9
Epitope-associated and specificity-focused features of EV71-neutralizing antibody repertoires from plasmablasts of infected children.来自受感染儿童浆母细胞的肠道病毒71型中和抗体库的表位相关及特异性聚焦特征
Nat Commun. 2017 Oct 2;8(1):762. doi: 10.1038/s41467-017-00736-9.
10
Co-circulation of multiple subtypes of enterovirus A71 (EV- A71) genotype C, including novel recombinants characterised by use of whole genome sequencing (WGS), Denmark 2016.肠道病毒A71(EV-A71)C基因型多种亚型的共同传播,包括通过全基因组测序(WGS)鉴定的新型重组体,丹麦,2016年。
Euro Surveill. 2017 Jun 29;22(26). doi: 10.2807/1560-7917.ES.2017.22.26.30565.